# A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Source: https://onco.cc/trials/nct06003231/  
OnCo record `nct06003231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin in non-small-cell lung cancer, ovarian cancer, endometrial cancer and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.

## Summary

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 is a phase 2 interventional study registered as NCT06003231 by Seagen, a wholly owned subsidiary of Pfizer, with 120 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2026-03-27. Interventions recorded: disitamab vedotin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06003231
- Phase: 2
- Setting: A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06003231: https://clinicaltrials.gov/study/NCT06003231

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/)

---
JSON: https://onco.cc/api/v1/entities/nct06003231.json